Neogenomics announces chief executive officer appointment

Chris smith named ceo effective august 15, 2022; interim ceo lynn tetrault to resume role of independent chair of the board ft. myers, fl / accesswire / july 21, 2022 / neogenomics, inc. (nasdaq:neo), a leading provider of oncology testing and global contract research services, today announced that industry veteran chris smith has been appointed chief executive officer and a member of the board of directors effective august 15, 2022.
NEO Ratings Summary
NEO Quant Ranking